Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Around 7% of the Indian population suffers from IBS
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Subscribe To Our Newsletter & Stay Updated